Related Experiment Video
Updated: Apr 21, 2026
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma
Jonathan A Ledermann1, Daniela Luvero, Aaron Shafer
1*UCL Cancer Institute and UCL Hospitals, London UK; †Hartford Hospital, Hartford, CT; ‡University of Louisville School of Medicine, Louisville, KY; §IRCCS San Raffaele Hospital, Milan, Italy; ∥The Prince of Wales Hospital Randwick, New South Wales, Australia; ¶Gynecologic Oncology Center, Kiel, Germany; #Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; **Seoul National University College of Medicine, Seoul, Korea; ††Paris Descartes University, Cochin-Hôtel Dieu, Paris; ‡‡Princess Margaret Hospital, Toronto, Canada; and §§MD Anderson Cancer Centre, Houston, TX.
Abstract:
Mucinous carcinomas of the ovary can be primary or metastatic in origin. Improvements in the pathological diagnosis have increased the ability to distinguish between primary and metastatic ovarian cancers and shown that primary mucinous carcinomas are a rare subtype of ovarian cancer. Most tumors are diagnosed at an early stage, and the prognosis after surgery is good. Advanced or recurrent mucinous carcinoma of the ovary responds poorly to current cytotoxic treatments, and the prognosis is poor. Here, we review the guidelines for surgery and the results of treatment of advanced and recurrent disease. Chemotherapy with platinum and paclitaxel is currently used to treat advanced disease, but the effect of these drugs is modest, and new treatments are needed.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020